Ghanemi Abdelaziz, Yoshioka Mayumi, St-Amand Jonny
Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, QC G1V 0A6, Canada.
Functional Genomics Laboratory, Endocrinology and Nephrology Axis, CHU de Québec-Université Laval Research Center, Québec, QC G1V 4G2, Canada.
Medicines (Basel). 2023 May 16;10(5):32. doi: 10.3390/medicines10050032.
Coronavirus disease-2019 (COVID-19) has had and will have impacts on public health and health system expenses. Indeed, not only it has led to high numbers of confirmed COVID-19 cases and hospitalizations, but its consequences will remain even after the end of the COVID-19 crisis. Therefore, therapeutic options are required to both tackle the COVID-19 crisis and manage its consequences during the post COVID-19 era. Secreted protein acidic and rich in cysteine (SPARC) is a biomolecule that is associated with various properties and functions that situate it as a candidate which may be used to prevent, treat and manage COVID-19 as well as the post-COVID-19-era health problems. This paper highlights how SPARC could be of such therapeutic use.
2019冠状病毒病(COVID-19)已经并将继续对公共卫生和卫生系统费用产生影响。事实上,它不仅导致了大量COVID-19确诊病例和住院病例,而且即使在COVID-19危机结束后,其后果仍将存在。因此,需要有治疗方案来应对COVID-19危机,并在COVID-19后时代管理其后果。富含半胱氨酸的酸性分泌蛋白(SPARC)是一种生物分子,具有多种特性和功能,使其成为可用于预防、治疗和管理COVID-19以及COVID-19后时代健康问题的候选物。本文重点介绍了SPARC如何具有这种治疗用途。